Omega Diagnostics Group PLC Mologic CE Mark Rapid Antigen Test
December 24 2020 - 7:00AM
RNS Non-Regulatory
TIDMODX
Omega Diagnostics Group PLC
24 December 2020
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Mologic CE Mark Rapid Antigen Test
Omega (AIM: ODX), the medical diagnostics company focused on
CD4, infectious diseases and food intolerance, welcomes the news
that Mologic Ltd ("Mologic") has received CE Mark for it's
professional-use COVID-19 Rapid Antigen Test.
In June this year, the Company signed a material transfer
agreement ("MTA") with Mologic providing access to raw materials
and know-how to manufacture their lateral flow antigen test. The
test will provide health professionals an accurate detection of the
nucleoprotein of the SARS-CoV-2 virus in respiratory swabs.
As announced at the Interim results in November 2020, Omega has
now established its technology transfer team and look forward to
updating shareholders in the New Year on how the technology
transfer and CE Mark is going, so the Company can sell the Rapid
Test under Omega's VISITECT (R) brand.
Colin King, CEO of Omega Diagnostics, said: "We welcome the news
that Mologic has received CE Mark for its Rapid Antigen Test, and
are excited about completing the technology transfer and CE Marking
in the New Year."
Contacts:
Omega Diagnostics Group PLC Tel: 01259 763 030
Bill Rhodes, Interim Non-Executive www.omegadiagnostics.com
Chairman
Colin King, Chief Executive
Kieron Harbinson, Group Finance
Director
finnCap Ltd Tel: 020 7220 0500
Geoff Nash/Edward Whiley (Corporate
Finance)
Alice Lane (ECM)
Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFLFSLFALSFII
(END) Dow Jones Newswires
December 24, 2020 07:00 ET (12:00 GMT)
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Apr 2024 to May 2024
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From May 2023 to May 2024